Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare disease therapies, has announced an inducement grant of 48,561 restricted stock units to 17 newly hired non-executive officers. The grants were approved by the company's compensation committee under the Ultragenyx Employment Inducement Plan on September 16, 2025.
The restricted stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) for employment inducement awards.
[]Ultragenyx Pharmaceutical (NASDAQ: RARE), una società biofarmaceutica specializzata in terapie per malattie rare e ultra-rare, ha annunciato una concessione inducente di 48.561 unità azionarie vincolate a 17 nuovi dirigenti non esecutivi assunti. Le concessioni sono state approvate dal comitato di compensazione dell'azienda nell'ambito del Ultragenyx Employment Inducement Plan il 16 settembre 2025.
Le unità azionarie vincolate prevedono un piano di vesting quadriennale, con il 25% delle azioni che matura annualmente in corrispondenza della data di assegnazione, previa continuazione dell'impiego. Questa concessione è conforme alla Nasdaq Listing Rule 5635(c)(4) per premi di assunzione.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una empresa biofarmacéutica especializada en terapias para enfermedades raras y ultra raras, ha anunciado una concesión inducida de 48.561 unidades de acciones restringidas a 17 nuevos directivos no ejecutivos contratados. Las concesiones fueron aprobadas por el comité de compensación de la empresa bajo el Ultragenyx Employment Inducement Plan el 16 de septiembre de 2025.
Las unidades de acciones restringidas cuentan con un plan de vesting de cuatro años, con el 25% de las acciones consolidándose anualmente en la fecha de otorgamiento, sujeto a la continuidad en el empleo. Este otorgamiento cumple con la Nasdaq Listing Rule 5635(c)(4) para premios por inducción de empleo.
Ultragenyx Pharmaceutical (NASDAQ: RARE)은(는) 희귀 및 초희귀 질환 치료제를 전문으로 하는 생물의약품 회사로, 48,561주식제한부여를 신규 채용된 17명의 비임원에게 부여하는 유인 보상 부여를 발표했습니다. 이 보상은 2025년 9월 16일에 Ultragenyx 고용 유도 계획에 따라 회사의 보상 위원회에서 승인되었습니다.
제한 주식 유닛은 4년 vesting 일정을 특징으로 하며, 수여일의 해마다 주식의 25%가 가속 없이 실현될 예정이며, 계속 고용 여부에 따라 달라집니다. 이 부여는 인력 유도 보상에 대한 Nasdaq Listing Rule 5635(c)(4)을 준수합니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE), une société biopharmaceutique spécialisée dans les thérapies pour les maladies rares et ultra-rares, a annoncé une attribution incitative de 48.561 unités d'actions restreintes à 17 nouveaux cadres non dirigeants recrutés. Les attributions ont été approuvées par le comité de rémunération de l'entreprise dans le cadre du Ultragenyx Employment Inducement Plan le 16 septembre 2025.
Les unités d'actions restreintes disposent d'un plan de vesting sur quatre ans, avec 25% des actions qui se libèrent chaque année à la date d'attribution, sous réserve de l'emploi continu. Cette attribution est conforme à la Nasdaq Listing Rule 5635(c)(4) concernant les récompenses d'embauche.
Ultragenyx Pharmaceutical (NASDAQ: RARE) hat eine Anreizgewährung von 48.561 eingeschränkten Aktieneinheiten an 17 neue fest angestellte Führungskräfte angekündigt. Die Zuwendungen wurden vom Vergütigungsausschuss des Unternehmens im Rahmen des Ultragenyx Employment Inducement Plan am 16. September 2025 genehmigt.
Die eingeschränkten Aktieneinheiten verfügen über einen Vesting-Plan über vier Jahre, bei dem jährlich zum Jahrestag der Zuteilung 25% der Aktien bei fortbestehendem Arbeitsverhältnis freigegeben werden. Diese Zuwendung entspricht der Nasdaq Listing Rule 5635(c)(4) für Beschäftigungsanreize.
Ultragenyx Pharmaceutical (NASDAQ: RARE)، شركة أدوية حيوية متخصصة في علاجات الأمراض النادرة والنادرة جدًا، أعلنت عن منحة تحفيزية من 48,561 وحدة أسهم مقيدة لـ 17 مديرًا جديدًا غير تنفيذي تعيينوا. تمت الموافقة على المنح من قبل لجنة التعويض بالشركة وفقًا لـ خطة تحفيز التوظيف Ultragenyx Employment Inducement Plan في 16 سبتمبر 2025.
تتميز وحدات الأسهم المقيدة بـ جدول احتراف لمدة أربع سنوات، مع تقاسم 25% من الأسهم سنويًا في تاريخ المنحة، رهناً باستمرار العمل. هذه المنحة تتوافق مع Nasdaq Listing Rule 5635(c)(4) فيما يخص مكافآت التحفيز الوظيفي.
Ultragenyx Pharmaceutical (NASDAQ: RARE)，是一家专注于罕见及超罕见疾病治疗的生物制药公司，宣布向 17名新聘非执行官人员提供 48,561份受限股票单位的诱导性授予。该授予于 2025年9月16日经公司薪酬委员会在 Ultragenyx Employment Inducement Plan框架下批准。
受限股票单位具有四年归属期，在授予日周年时每年归属25%，前提是持续雇佣关系。该授予符合 Nasdaq Listing Rule 5635(c)(4) 关于就业诱导性奖励的规定。
- None.
- None.
NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of the company’s common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
What type of stock compensation did Ultragenyx (RARE) grant to new employees in September 2025?
What is the vesting schedule for Ultragenyx's (RARE) September 2025 restricted stock units?
How many new non-executive officers received Ultragenyx (RARE) stock grants in September 2025?
Under which Nasdaq rule did Ultragenyx (RARE) issue the September 2025 inducement grants?
